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In oncology, preclinical and early clinical data increasingly support the use of a number of 
candidate “non-cancer” drugs in an off-label setting against multiple tumor types. In particular, 
metabolically targeted drugs show promise as adjuvant chemo and radiosensitizers, improving 
or restoring sensitivity to standard therapies. The time has come for large scale clinical studies 
of off-label drugs in this context. However, it is well recognized that high-cost randomized 
controlled trials may not be an economically viable option for studying patent-expired off-label 
drugs. In some cases, randomized trials could also be considered as ethically controversial. 
This perspective article presents a novel approach to generating additional clinical data of 
sufficient quality to support changes in clinical practice and relabeling of such drugs for use in 
oncology. Here, we suggest that a pluralistic evidence base and triangulation of evidence can 
support clinical trial data for off-label drug use in oncology. An example of an off-label drug 
protocol brought to the clinic for glioblastoma patients is presented, along with preliminary 
retrospective data from the METRICS study (NCT02201381). METRICS is a novel participant-
funded, open-label, non-randomized, single-arm real-world study designed to gather high-
quality evidence on the safety, tolerability, and effectiveness of four off-label metabolically 
targeted medicines as an adjunctive cancer treatment for glioblastoma patients.
Keywords: off-label, glioblastoma, metformin, atorvastatin, mebendazole, doxycycline, metabolic targeting, 
pluralistic evidence
THE PROBLEM
The economic and health burden of cancer are increasing, due in part to the rising incidence of many 
cancers, improving and earlier diagnosis, a growing and aging population, and the huge costs of 
new cancer treatments (Sullivan et al., 2011; Savage and Mahmoud, 2015; Fitzmaurice et al., 2018). 
The current system of drug research and development is increasingly considered economically 
unsustainable (Jackson and Sood, 2011), with an average delay from initial identification of a novel 
agent to regulatory approval of over 10 years (Paul et al., 2010), and costs from approximately $684 
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million to $2.7 billion per drug (DiMasi et al., 2016; Prasad and 
Mailankody, 2017). Furthermore, recent research has found that 
a significant number of novel cancer drugs enter the market 
without definitive evidence of benefit for overall survival or quality 
of life (Davis et al., 2017). Increasingly, healthcare systems are 
needing to deliver more with less, and mining the pharmacopeia 
of existing drugs for potential novel indications could offer an 
economically efficient path to new cancer treatments (Stoller et 
al., 2017; Prager et al., 2018).
OFF-LABEL DRUG USE IN ONCOLOGY
Off-label use, and relabeling, of existing licensed medicines 
for treatment of cancer can be quicker and more cost-effective 
compared with untested drugs, as these licensed medicines 
already have well-established safety profiles, are often well 
tolerated, and usually have extensive preclinical and clinical 
evidence supporting their safe use in humans (Bertolini et al., 
2015; Pantziarka et al., 2017; Sleire et al., 2017).
The anticancer properties of a variety of drugs, licensed for 
non-cancer–related conditions, are becoming widely recognized, 
and a number of initiatives exist that aim to generate evidence 
enabling the prescribing of off-label drugs in cancer (Pantziarka 
et al., 2014a; Hernandez et al., 2017). Even thalidomide has found 
new purpose in the treatment of myeloma (Palumbo et al., 2008). 
Promising evidence gathered from mechanistic, preclinical, and 
epidemiological studies has led to the extensive study of several off-
label drugs for use in cancer. For example, the antihyperglycemic 
metformin and atorvastatin (a lipophilic statin) are two veteran 
licensed drugs with large epidemiological evidence bases built over 
decades supporting their use in cancer (Sahra et al., 2010; Altwairgi, 
2015). Although some prospective randomized clinical trials 
are now underway investigating their use in cancer, progress in 
reaching this point has been slow. Prospective studies are generally 
small, focusing on mechanism of action or surrogate markers of 
efficacy (Chae et al., 2015; Chae et al., 2016). Significant barriers 
hamper efforts to provide sufficient quality evidence on the off-label 
use of these medicines in cancer, for gaining a marketing license for 
a new indication (Hernandez et al., 2017; Verbaanderd et al., 2017).
Despite the existence of promising evidence for statins and 
metformin in cancer, there is still a paucity of good quality 
prospective clinical data. One major reason for this is the lack of 
financial incentive to run large randomized controlled trials (RCTs) 
(Breckenridge and Jacob, 2018). As these drugs are off-patent, 
there is currently no financial incentive for companies to take on 
the research and development as well as clinical study expenditure 
(Breckenridge and Jacob, 2018). Thus, running large studies in off-
label drugs for alternative indications, particularly those that are 
generically available, remain commercially nonviable and prevent 
the clinical development of promising anticancer treatments.
Across the breadth of the pharmacopeia, a prerequisite to the 
expansion of their off-label use and subsequent relabeling is the 
establishment of a high-quality evidence base for the new use. 
A major concern from purchasers and providers of treatments is 
the lack of good quality evidence base supporting off-label use 
(Dresser and Frader, 2009; Pfister, 2012). In the UK, clinicians 
are permitted to prescribe licensed medicines off-label, if they are 
satisfied that there is no other licensed alternative that would meet 
the patient’s needs and can be sure that there is sufficient evidence 
base and/or experience of using the medicine to show its safety and 
efficacy. However, the UK’s General Medical Council also makes 
it clear that when using medicines off-label, greater responsibility 
(and potential liability) falls on the prescribing clinician than when 
these medicines are used within the terms of their license. It is 
therefore understandable that clinicians may currently be reluctant 
to do this. In cancer, the rationale behind the Lord Saatchi’s failed 
medical innovation bill was to support such a practice by removing 
the perceived fear doctors have in assuming possible negligence 
action in common law by pursuing new off-label uses (Dyer, 
2015). Although off-label prescribing is already commonplace in 
non-cancerous conditions, this is not the case for the use of non-
chemotherapy drugs in oncology. Perhaps, an ethical off-label use 
for these safe and well-tolerated treatments might be their use as 
an adjunctive therapy on top of the current standard of care (SoC)? 
This would ensure that the patient receives off-label treatments 
only in addition to therapies currently labeled for cancer.
CREATING AN EVIDENCE BASE—
PLURALISTIC EVIDENCE AND 
TRIANGULATION
Regulatory authorities, healthcare purchasers, and clinicians 
require high-quality reliable evidence that can support the off-
label use of drugs and relabeling for new indications. But how 
can this evidence be generated, in a situation where the funding 
of phase III trials is not commercially viable, and the ethics of 
placebo-controlled trials are increasingly under scrutiny, with 
their real-world relevance under question (Daugherty et al., 2008; 
Hamilton and Peppercorn, 2011; Corrigan-Curay et al., 2018)?
Pluralistic evidence as a methodological research approach 
can be used for clinical development programs where it is 
impossible, impractical, or unethical to follow a more traditional 
RCT-based approach (Tucker and Reed, 2008; Fives et al., 2017). 
In accordance with this, a pluralistic approach could therefore 
be applied when there is no commercial rationale for running 
a large randomized controlled clinical study to help establish 
causality for the efficacy of an off-label treatment in cancer.
Pluralistic evidence in support of a new product or new purpose 
is now in some cases accepted by regulatory authorities in place 
of an RCT. For example, during serious emergency epidemics, 
the World Health Organization now accepts the method called 
monitored emergency use of unregistered interventions, as seen in 
the use of Merck’s recombinant vesicular stomatitis virus vaccine 
in the recent Ebola outbreak in the Democratic Republic of Congo 
(Adebamowo et al., 2014; Calain, 2018). The European Medicines 
Agency approach to medicines adaptive pathways to patients also 
accepts the use of observational data to confirm early phase work 
on new products (Gannedahl et al., 2018). However, there remains 
the question of how to improve the quality of the evidence base, 
such that science can produce a more complete causal picture 
while minimizing the attendant biases, so that practitioners can 
learn what really works, and for whom.
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To develop a pluralistic evidence base, all available sources 
and types of data should be considered, including in silico 
bioinformatics, laboratory studies on mechanisms of action, in 
vitro experiments on human biopsies, in vivo animal models, 
quality of life data, clinical trials of off-label drug use, etc. (Liu 
et al., 2013; Fives et al., 2017). As illustrated in the glioblastoma 
multiforme (GBM) case study, the pluralistic approach involves 
designing studies and generating new data from a range of sources 
to support causality. In this context, triangulation has an important 
role in using information from disparate sources in order to 
corroborate the findings of any single strategy or dataset (Munafò 
and Smith, 2018). Unlike traditional clinical study approaches, 
such as RCTs, triangulation does not aim to answer a predefined 
hypothesis or directly establish causality. Rather, triangulation 
can assess the external validity and strengthen interpretation of 
different datasets (Denzin, 1973; Rutherford et al., 2010).
In 2017, the European Union published a paper on the use of off-
label drugs across Europe in all indications, including oncology, and 
set policy objectives to repurpose old drugs into new indications 
(Weda et al., 2017). This paper highlighted the importance of 
indication-driven trials with combinations of medicines and 
emphasized that the collection of real-world evidence is needed to 
give confidence in the efficacy of off-label treatments. In the light 
of this, we propose that a pluralistic, real-world approach with high 
external validity and auxiliary studies to improve internal validity 
offers a viable alternative to randomized controlled studies when 
these are not feasible. This approach can provide data of sufficient 
quality to “fill the evidence gap” for the efficacy and safety of off-
label medicines in the treatment of cancer (Roche et al., 2014).
OFF-LABEL DRUG USE FOR 
GLIOBLASTOMA—THE METRICS STUDY
Background
We describe here our experience of developing a study for an off-
label drug protocol for patients with cancer as an adjuvant therapy 
to SoC. The METRICS study (NCT02201381) is a novel open-
label non-randomized, single-arm realworld study designed 
to gather high-quality evidence on the safety, tolerability, and 
effectiveness of four off-label metabolically targeted medicines 
(metformin, atorvastatin, mebendazole, and doxycycline) as an 
adjunctive cancer treatment.
There are two parts to METRICS: 1) a proof-of-concept 
retrospective analysis on the outcomes of GBM patients who 
have already received the off-label protocol and 2) a prospective 
analysis for newly enrolled patients with any cancer type, 
including GBM. Preliminary results from the retrospective 
analysis in patients with GBM are presented. These results 
provide the first of several planned datasets from different 
sources (collectively termed METRICS plus), which we believe 
in combination will provide good quality, robust evidence to help 
determine the causality of the adjuvant cancer protocol.
Along with the METRICS study, METRICS plus will comprise 
the following additional pillars of evidence required to enhance 
scientific value: 1) comparison of clinical endpoints with those of 
matched control patients (supplied by Public Health England) 
receiving SoC only; 2) two mechanism-of-action imaging studies 
pertaining to the new treatment; 3) animal data evaluating the 
protocol in a highly translatable setting (namely, a veterinary clinic 
treating canine cancer), using a randomized controlled design. 
These studies can be analyzed in their totality to determine the 
likely causality of the new treatment on the outcomes observed. The 
analysis of the summed datasets will be evaluated with Bayesian 
methodologies that can readily incorporate evidence from different 
sources.
Together, the studies of METRICS plus comprises the central 
pillars of what we term methodological pluralism. We suggest 
that such an approach may help to solve some of the difficulties 
with RCTs under these challenging circumstances and will also 
help provide a more complete picture of causality than a simple 
RCT would allow. It further allows greater scope for triangulation, 
which is becoming an increasingly important notion as trial data 
in many cases appear difficult to reproduce in the real-world 
setting (Munafò and Smith, 2018).
Rationale for the Adjuvant Drug 
Combination
The combination of off-label metabolic medicines used in METRICS 
(metformin, atorvastatin, mebendazole, and doxycycline) was 
chosen following an analysis of existing mechanistic and clinical 
data. These medications modulate interconnected intracellular 
pathways involved in cancer cell growth, proliferation, apoptosis, 
and angiogenesis, focusing on metabolic pathways (Sahra et al., 
2010; Gazzerro et al., 2012; Pantziarka et al., 2014b; Ampuero and 
Romero-Gomez, 2015; Barbie and Kennedy, 2015). Additionally, 
metformin, doxycycline, and atorvastatin disrupt cancer cell 
membrane and signaling proteins and systems, including matrix 
metalloproteinases (Tang et al., 2013; Matusewicz et al., 2015; 
Peiris-Pagès et al., 2015; Babcook et al., 2016; Lei et al., 2017). 
Metformin also affects epigenetic upregulation of apoptotic factors 
and downregulation of oncogenic transcription factors such as 
STAT3 (overlapping with doxycycline for the latter mechanism) 
(Deng et al., 2012; Yu et al., 2017).
Importantly, preclinical studies show that adjuvant application 
of statins, metformin, or mebendazole can potentially enhance 
cytotoxic activity of standard anticancer treatments and reduce 
resistance (Cemeus et al., 2008; Jiang et al., 2014; Markowitz et al., 
2017; Kipper et al., 2018). In aggressive non-small cell lung cancer, 
metformin has been shown to be radio and chemo-sensitizing 
in both preclinical and in early clinical studies (Troncone et al., 
2017). Crucially, both metformin and doxycycline also disrupt the 
metabolic pathways of cancer stem cells, which are suspected to be 
the initiators of resistance and recurrence in tumors (Mohammed 
et al., 2013; Lamb et al., 2015; De Francesco et  al., 2017). 
Mebendazole, metformin, and statins also indirectly modulate 
the immune system, and in addition, the latter two cause reduction 
in availability of glucose and low-density lipoproteins to cancer 
cells (Rosilio et al., 2014; Babcook et al., 2016; Blom et al., 2017). 
Supporting their use in brain cancers, metformin, atorvastatin, 
doxycycline and mebendazole have been shown to distribute 
through the blood brain barrier into the CNS (Nau et al., 2010; 
Wood et al., 2010; Bai et al., 2015; Koenig et al., 2017).
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Numerous epidemiological and small prospective studies 
have concluded that further investigations are warranted for the 
use of metformin and statins in cancer (Chae et al., 2015; Chae 
et al., 2016), while mechanistic studies and case reports have 
advocated the use of doxycycline and mebendazole (Pantziarka et 
al., 2014b; Barbie and Kennedy, 2015). The combination of these 
four safe and well-tolerated medicines was selected to cover a 
diverse number of metabolic pathways, maximizing the potential 
efficacy across tumor types. In GBM, the need for new treatments 
is acute. GBM treatment is limited to surgery, radiotherapy, and 
oral temozolomide, resulting in a median overall survival (OS) of 
just 14.6 months for patients with GBM (Brodbelt et al., 2015).
Summary of Study Methodology and 
Retrospective Analysis of GBM Patients
Patients and Methods
Patients were recruited at a private clinic and gave written, informed 
consent in accordance with the Declaration of Helsinki. In 
addition to being made aware of the evidence base for the off-label 
drug use, its limitations, and the side-effect profile, patients were 
informed that by attending the clinic and paying for treatment, 
they were directly funding the research in which they were 
participating. Participant-funded research initiatives are a relatively 
new phenomenon, but their use is growing (Vayena et al., 2016). 
METRICS was approved by the East Midlands—South Leicester 
Research Ethics Committee in the UK. During the regulatory 
process, the UK Medicines and Healthcare Products Regulatory 
Agency and the national ethics committee defined a new study 
classification of “Interventional Service Evaluation” to describe the 
observational, pharmacodynamic data collection from patients.
The retrospective analysis consisted of 95 patients with 
advanced GBM stage IV (GBM) who attended the clinic between 
2013 and 2016. Patients could be enrolled at any time from the 
presentation of their GBM onwards, i.e., newly diagnosed or at 
recurrence/progression. All patients continued to receive their SoC 
cancer treatments outside the clinic, mostly within the National 
Health Service. Every clinic visit generated correspondence to the 
patient’s primary care physician and the National Health Service 
oncology team (where consent to do so was obtained from the 
patient), from whom relevant patient data were obtained.
The primary endpoint was OS (defined as time from cancer 
diagnosis until death from any cause). Patients who were still 
alive at the time of analysis (clinical cutoff) and patients lost to 
follow-up were censored at their last clinical assessment date. 
All patient data were analyzed on an intention-to-treat basis 
and subjected to a time-to-event analysis, conducted by an 
independent third party (Cytel Inc, France). Full inclusion and 
exclusion criteria and further methodological details can be 
found at https://clinicaltrials.gov/ct2/show/NCT02201381.
Preliminary Data
Demographic and baseline characteristics were similar in 
this retrospective cohort to other published GBM cohorts 
(Stupp et al., 2005; Brodbelt et al., 2015). Mean (SD) age was 
53.7 (13.52) years, and the majority of patients were male [65 
patients (68.4%)]. The median time from diagnosis to starting 
the adjuvant protocol was 6.64 months. Although the study is 
ongoing, and this is not a planned interim analysis, the cohort 
as a whole (n = 95) had a median survival of 26.3 months and a 
two-year survival of 55.8%, with the censoring of patients shown 
in the Kaplan-Meier plot (Figure 1A). The SoC treatments 
received alongside the-off-label medications were: surgery, 
chemotherapy and radiotherapy (72.2%), biopsy, chemotherapy 
and radiotherapy (15.6%), radiotherapy alone (4.4%) and others 
(7.8%) (Figure 1A). The median OS for this unselected cohort of 
patients with GBM who received off-label medications alongside 
optimal SoC (i.e. surgery, chemotherapy and radiotherapy) was 
27.1 months (95% CI 24.0; 37.6) from diagnosis, with a 2-year 
survival of 64.0%. These analyses compares favorably with other 
GBM cohorts receiving optimal SoC alone, with a median OS of 
14.8 months (CI 14.2; 15.4) in the Public Health England dataset 
(Brodbelt et al., 2015) and 15.8 months (CI 13.2; 16.8) in a study 
by the European Organisation for Research and Treatment of 
Cancer (Stupp et al., 2005), with a 2-year survival of 28.7% and 
26.5%, respectively (Figure 1B).
This patient population is prone to experiencing symptoms 
related to both their disease as well as the SoC treatment 
received. Patients were closely monitored with respect to their 
symptomatology, serological and biochemical parameters, and 
performance status. The adjunctive combination of off-label 
medicines was generally well tolerated, with 85.3% (81/95) 
of this GBM cohort taking all four medications concurrently 
without issue.
The adverse event profile was as expected for these licensed 
medications. The most frequently reported conditions were 
gastrointestinal in nature (e.g., diarrhea, bloating, nausea), most 
commonly associated with metformin; and muscle and joint aches, 
linked with statin use. The overwhelming majority of adverse events 
reported were easily manageable and did not require interruption 
or cessation of the protocol. No drug-related SAEs were reported.
Of the 14.7% (14/95) of the patients who were not able to 
take all four protocol medications, 3.2% (3/95) comprised 
patients who were prevented from starting one or more of the 
medications due to clinical contraindications or drug interactions 
with existing medications they were taking. The other 11.5% 
(11/95) consisted of patients who either reported significant side 
effects attributable to one or more of the drugs or patients with 
potentially clinically relevant findings in one or more blood tests 
(i.e., full blood count, renal or liver function tests), which may or 
may not have been attributable to the protocol medications, but 
nevertheless required cessation of one or more of the protocol 
drugs for safety reasons.
CONCLUSIONS
The use of pluralistic evidence gathering in a real-world clinical 
setting offers a feasible alternative data collection model to 
break the financial deadlock preventing the study of off-label 
medications in oncology. The novel real-world study of off-
label medicines presented here provides a proof of concept 
for generating clinical data when traditional RCTs are not an 
option. The initial findings with an adjuvant antimetabolic 
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protocol in the setting of GBM SoC treatment are encouraging, 
with a median OS in the retrospective analysis of 27.1 months. 
A direct comparison with matched controls will be conducted 
in the future to establish whether this apparent effect on overall 
survival is different from standard of care. A pluralistic evidence 
base involves looking at disparate sources for generating data. 
In our example, a prospective phase of the METRICS study will 
form an additional part of the pluralistic evidence base, along 
with mechanistic clinical imaging studies in the case of GBM and 
an RCT of the adjuvant protocol for canine cancer. The external 
validity of these different studies can be assessed by triangulation, 
which also strengthens the interpretation of their findings.
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FIGURE 1 | Overall survival of patients with glioblastoma multiforme (GBM) receiving the METRICS protocol in addition to optimal standard of care (SoC).  
(A) Kaplan–Meier plot of survival in patients with GBM receiving the METRICS protocol in addition to SoC, with uncensored patient numbers over time and the 
percentages of patients receiving the SoCs. The pie chart shows the distribution of SoC treatments. (B) Median overall survival and 2-year survival of patients 
receiving optimal SoC alongside the off-label medications in the METRICS study cohort compared with other GBM patient cohorts receiving optimal SoC. EORTC, 
European Organisation for Research and Treatment of Cancer (Stupp et al., 2005), Public Health England (Brodbelt et al., 2015).
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